Supplemental / Web tables

Table e-1: NMOSD characteristics summary

ON = optic neuritis. TM = Transverse myelitis. LETM = Longitudinally extensive transverse myelitis. * Some patients received more than one treatment because intolerance or lack of response to the first agent.

Characteristic	Values
Number of women	60
Mean age (years) at NMOSD onset (SD)	46.4 (13.1)
NMOSD onset – presenting features	
Brain	1
Brainstem	5
Brainstem + brain + ON or TM	5
Bilateral optic neuritis	2
Optic neuritis	23
Optic neuritis + LETM	2
TM/LETM	22
Form of disease – subgroup within NMOSD	
Brain/brainstem	2
NMO + brain/brainstem	5
NMO	21
Optic neuritis (single & recurrent)	10 (1 & 9)
TM/LETM (single & recurrent)	22 (4 & 18)
Mean time (months) to start immunosuppressive treatment	
from disease onset (SD)	47.2 (57.5)

Immunosuppressive treatments (taken for ≥ 3 months)*	
Prednisolone alone	25
Azathioprine +/- prednisolone	27
Methotrexate +/- prednisolone	7
Mycophenolate mofetil +/- prednisolone	4
Cyclosporine + prednisolone	2
Rituximab +/- prednisolone	3
Mitoxantrone	2
Mean annual relapse rate before treatment	0.77
Mean annual relapse rate during treatment	0.2
Evidence of ≥ 1 other autoimmune disorder	63.3%
Evidence of ≥ 2 other autoimmune disorders	16.7%

Table e-2: Cohort obstetric details

Values
60
126
28.5 (5.48)
2.43 (1-4)
16.1 (14.2)
22 (17.5%)
11 (12.9%)
13 (11.5%)

Table e-3: Multivariate Logistic Regression for variables associated with increased risk of preeclampsia.

Independent Variable	Odds Ratio	95%-CI	P val (*sig)
(n = no. preeclampsia / eligible pregnancies)			
Miscarriage in last pregnancy (2/3)	27.3	1.57 – 475	*0.023
≥ 2 other autoimmune disorders (6/19)	8.01	1.03 – 62.6	*0.047